Elicio Therapeutics, Inc. (ELTX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Elicio Therapeutics, Inc. (ELTX) Healthcare & Pipeline Overview

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of immunotherapies, primarily focused on its lead candidate ELI-002, an AMP therapeutic vaccine targeting KRAS-driven cancers, positioning it within the competitive oncology therapeutics landscape.

What Is the Investment Thesis for ELTX?

Elicio Therapeutics presents a notable research candidate within the biotechnology sector, driven by its innovative AMP technology and promising clinical pipeline. The primary value driver is the clinical progress of ELI-002, targeting KRAS-driven cancers, a substantial market with limited effective treatments. Successful clinical trial outcomes for ELI-002 could lead to significant market adoption and revenue generation. Key growth catalysts include upcoming clinical trial data releases and potential partnerships with larger pharmaceutical companies. However, the investment is subject to risks inherent in clinical-stage biotech companies, including clinical trial failures, regulatory hurdles, and the need for substantial additional funding. The company's market capitalization is $0.22 billion as of 2026-05-10.

Based on FMP financials and quantitative analysis

ELTX Key Highlights

Elicio Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and other diseases.

• The company's lead product candidate, ELI-002, is an AMP therapeutic vaccine for the treatment of KRAS-driven cancers, representing a significant market opportunity.
• Elicio's proprietary Amphiphile (AMP) platform enhances the delivery of immunogens directly to the lymph nodes, amplifying the immune response.
• The company is developing a pipeline of novel immunotherapies, including vaccines and adjuvants, targeting various cancer mutations and hematological cancers.
• Elicio Therapeutics is headquartered in Boston, Massachusetts, a hub for biotechnology innovation and investment.

Who Are ELTX's Competitors?

ELTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ELTX's Key Strengths?

Proprietary AMP technology platform.

• Clinical-stage pipeline with lead candidate ELI-002.
• Experienced management team.
• Focus on unmet needs in cancer treatment.

What Are ELTX's Weaknesses?

Limited financial resources as a clinical-stage company.

• Dependence on the success of clinical trials.
• High R&D costs and regulatory hurdles.
• Competition from larger pharmaceutical companies.

What Could Drive ELTX Stock Higher?

Clinical trial data releases for ELI-002 in KRAS-driven cancers.

• Potential partnerships with larger pharmaceutical companies.
• Advancement of ELI-007 and ELI-008 into clinical development.
• Expansion of the AMP technology platform to other diseases.
• Regulatory milestones and approvals for Elicio's immunotherapies.

What Are the Key Risks for ELTX?

Financial-distress signal — its Altman Z-Score of -13.54 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for ELI-002 and other product candidates.
• Regulatory delays or rejection of Elicio's immunotherapies.
• Competition from other companies developing cancer treatments.
• Need for substantial additional funding to support clinical development.
• Patent challenges and intellectual property disputes.

What Are the Growth Opportunities for ELTX?

• Expansion of ELI-002 Clinical Trials: Elicio has the opportunity to expand the clinical trials for ELI-002 to include additional KRAS-driven cancer subtypes and combination therapies. The KRAS mutation is prevalent in various cancers, including lung, colorectal, and pancreatic cancers, representing a multi-billion dollar market. Positive clinical data could lead to accelerated regulatory approval and market penetration, potentially generating significant revenue streams within the next 3-5 years.
• Development of ELI-007 and ELI-008 for BRAF and TP53 Mutant Cancers: Elicio's ELI-007 and ELI-008 programs target BRAF and TP53 mutant cancers, respectively. These mutations are also prevalent in various cancer types, creating substantial market opportunities. Successful development and clinical validation of these vaccines could broaden Elicio's pipeline and revenue potential, with potential market entry within 5-7 years.
• Partnerships and Licensing Agreements: Elicio can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its immunotherapies. These partnerships can provide access to additional funding, resources, and expertise, enhancing Elicio's ability to bring its products to market. Such agreements could be established within the next 1-2 years.
• Application of AMP Technology to Other Diseases: Elicio's AMP technology has the potential to be applied to other diseases beyond cancer, such as infectious diseases and autoimmune disorders. Expanding the application of the AMP platform could open up new markets and revenue streams. Research and development in these areas could yield new product candidates within the next 3-5 years.
• Advancement of ELI-012 for mKRAS-driven Cancers: Elicio is developing ELI-012, a mKRAS TCR T cell AMP-lifier designed for combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. This innovative approach could significantly enhance the efficacy of T cell therapies, addressing a major limitation in current cancer treatment strategies. Successful development and clinical validation of ELI-012 could position Elicio as a leader in the field of T cell therapy enhancement, with potential market entry in 5-7 years.

What Are ELTX's Competitive Advantages?

• Proprietary Amphiphile (AMP) technology platform that enhances immune responses.
• Strong intellectual property portfolio protecting their immunotherapies.
• Clinical-stage pipeline of novel immunotherapies targeting specific cancer mutations.
• Experienced management team with expertise in immunotherapy development.
• Strategic partnerships with leading research institutions and pharmaceutical companies.

What Does ELTX Do?

Elicio Therapeutics, Inc., founded with the mission to revolutionize cancer treatment, is a clinical-stage biotechnology company dedicated to developing a pipeline of novel immunotherapies. The company's core technology revolves around its proprietary Amphiphile (AMP) platform, which enhances the delivery of immunogens directly to the lymph nodes, thereby amplifying the body's immune response. Elicio's lead product candidate, ELI-002, is an AMP therapeutic vaccine designed to treat KRAS-driven cancers, which are among the most prevalent and challenging to treat. Beyond ELI-002, Elicio is also developing a range of other immunotherapeutic candidates, including ELI-004, an AMP-modified CpG adjuvant; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designed for combination with mKRAS-targeted TCR T cell therapy. Headquartered in Boston, Massachusetts, Elicio Therapeutics aims to address significant unmet needs in cancer treatment by harnessing the power of the immune system.

What Products and Services Does ELTX Offer?

• Develop novel immunotherapies for the treatment of cancer and other diseases.
• Utilize their proprietary Amphiphile (AMP) platform to enhance immune responses.
• Create therapeutic vaccines targeting specific cancer mutations, such as KRAS, BRAF, and TP53.
• Develop AMP-modified adjuvants to improve the efficacy of vaccines.
• Design AMP-lifiers to enhance the activity of T cell therapies.
• Conduct clinical trials to evaluate the safety and efficacy of their immunotherapies.

How Does ELTX Make Money?

• Develop and patent novel immunotherapies.
• Conduct preclinical and clinical research to validate their products.
• Seek regulatory approval from agencies like the FDA.
• Potentially partner with larger pharmaceutical companies for commercialization.
• Generate revenue through product sales, licensing agreements, and research grants.

What Industry Does ELTX Operate In?

Elicio Therapeutics operates within the rapidly evolving biotechnology industry, specifically in the oncology therapeutics market. The industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. Elicio's AMP technology positions it to potentially capture a share of this market by offering more effective and targeted immunotherapies compared to traditional approaches. Competitors include major pharmaceutical companies and other biotech firms developing cancer vaccines and immunotherapies.

Who Are ELTX's Key Customers?

• Patients with cancer and other diseases who may benefit from immunotherapies.
• Healthcare providers who prescribe and administer these therapies.
• Pharmaceutical companies who may partner with Elicio for development and commercialization.
• Research institutions and government agencies who may fund research and development efforts.

Over the past six months, Elicio Therapeutics, Inc. insiders filed 4 SEC Form 4 transactions — 0 sales and 4 purchases. On net that is roughly 365K shares acquired (about $1.2M) — insiders putting money in tends to read as conviction.

ELTX Valuation & Market Position

With a $58.6M market cap, Elicio Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ELTX's quantitative score of 27/100 is below the peer average of 77/100.

Key Financial Metrics

Its free cash flow yield is -50.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.24 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -55.4%, the inverse of the P/E and a quick read on earnings relative to price.

Elicio Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.54 places it in the distress zone, a signal of elevated financial risk.

Elicio Therapeutics, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 17.3% below estimates on average.

Wall Street analysts project Elicio Therapeutics, Inc. revenue of about $20.0M for fiscal 2026, with EPS near $-2.04. The estimate reflects 4 contributing analysts.

Company Profile

Elicio Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Robert T. Connelly. ELTX has traded publicly since 2021.

ELTX Financials

ELTX Latest News

ELTX Analyst Consensus

ELTX MoonshotScore

Elicio Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources